For NSCLC patients with tumors expressing the ROS1 fusion gene, ROS1 inhibition might be an effective treatment protocol, and SDC4 plays a vital role as a common ROS1 fusion partner [84, 85]. This evidence concerns the gene SDC4 and non-small cell lung carcinoma.